Waters Corporation (WAT)

FairStock Score: 57/100 — STEADY

Key Financials

Strengths

• Exceptional 24.16% net margins and 29.28% ROE demonstrate sustainable competitive advantages in analytical instrumentation
• Strong recurring revenue model through consumables (chromatography columns, supplies) provides cash flow stability
• Fortress balance sheet with Altman Z-Score of 7.70 and manageable 0.60 D/E ratio
• Market leadership in liquid chromatography and mass spectrometry with high switching costs for customers
• Consistent free cash flow generation of $427M annually funds R&D and shareholder returns

Concerns

• Valuation is egregiously expensive at 27.8x P/E and 56.6x EV/EBITDA with negative margin of safety of -395%
• FCF yield of only 0.7% provides inadequate return on capital deployed, especially at current price
• Limited revenue and profit growth visibility with missing growth rate data suggesting maturation
• Beta of 1.20 means downside risk amplification if market corrects while holding at peak multiples

AI Analysis

Waters Corporation presents a classic case of quality at an unreasonable price. The business itself is genuinely excellent—24% net margins, 29% ROE, and $427M in free cash flow demonstrate pricing power and operational excellence in analytical instruments. Their duopoly-like position in liquid chromatography and mass spectrometry commands premium valuations for good reason. However, at 27.8x earnings with an EV/EBITDA of 56.6x, I'm simply unwilling to pay such a price. The Graham Number of $60.48 versus the current $299.63 reveals a margin of safety of negative 395%—we're paying nearly five times what fundamental analysis suggests. The Piotroski F-Score of 7/9 is respectable, and the Altman Z-Score of 7.70 indicates fortress-like financial stability with reasonable leverage at 0.60 D/E. Yet the FCF yield of merely 0.7% is inadequate compensation for this valuation risk. I appreciate the consistent 24% profit margins and the recurring revenue from consumables, but I cannot ignore that we're pricing in near-perfect execution indefinitely. The 1.20 beta suggests market-level volatility during downturns, which would be devastating at such multiples. This is a Buffett-quality business priced like a dot-com darling. I'd consider it attractive at $120-140, but today, I must respectfully pass.

Bull Case

Waters enjoys durable competitive moats, industry-leading margins, and recurring revenue streams that should support consistent mid-to-high single-digit growth. The essential nature of analytical instruments in pharma, biotech, and food safety provides secular tailwinds, and management's track record suggests disciplined capital allocation.

Bear Case

At nearly 28x earnings and 57x EBITDA, any deceleration in growth or margin compression would trigger a severe re-rating. The stock's 52-week high of $414 demonstrates speculative excess, and mean reversion toward intrinsic value could deliver 50%+ downside.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer